Trial Profile
A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Biosplice Therapeutics; Samumed
- 09 Nov 2021 Status has been changed to discontinued, according results presented at the ACR Convergence 2021.
- 28 Aug 2021 Results presented at the 2021 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 05 Jun 2021 Results of post-hoc efficacy analysis from three clinical studies: NCT02951026, NCT02536833 and NCT03122860 presented at the 22nd Annual Congress of the European League Against Rheumatism